A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Frequency Study of Intravenous Ketamine in Patients with Treatment-Resistant Depression

被引：0
|
作者：
Singh, Jaskaran [1 ]
Fedgchin, Maggie [1 ]
Daly, Ella [1 ]
De Boer, Peter [2 ]
Cooper, Kimberly [3 ]
Lim, Pilar [4 ]
Pinter, Christine [5 ]
Murrough, James [6 ]
Sanacora, Gerard [7 ]
Shelton, Richard [8 ]
Kurian, Benji [9 ]
Winokur, Andrew [10 ,11 ]
Fava, Maurizio [12 ,13 ]
Manji, Husseini [1 ]
Drevets, Wayne [1 ]
Van Nueten, Luc [2 ]
机构：
[1] Janssen Res & Dev LLC, Neurosci, Titusville, NJ USA
[2] Janssen Res & Dev LLC, Neurosci, Beerse, Belgium
[3] Janssen Res & Dev LLC, Clin Biostat, Spring House, PA USA
[4] Janssen Res & Dev LLC, Clin Biostat, Titusville, NJ USA
[5] Janssen Res & Dev LLC, GTM, Titusville, NJ USA
[6] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY USA
[7] Yale Univ, Sch Med, New Haven, CT USA
[8] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA
[9] UT Southwestern Med Ctr, Dept Psychiat, Dallas, TX USA
[10] Inst Living, Hartford, CT USA
[11] Univ Connecticut, Farmington, CT USA
[12] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA
[13] Harvard Univ, Sch Med, Boston, MA USA
来源：
BIOLOGICAL PSYCHIATRY | 2014年 / 75卷 / 09期
关键词：
Ketamine; Treatment-Resistant Depression; Efficacy; Safety;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
144
引用
收藏
页码：44S / 44S
页数：1
相关论文
共 50 条
  • [41] Efficacy and Safety of Yokukansan in Treatment-Resistant Schizophrenia: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
    Miyaoka, Tsuyoshi
    Furuya, Motohide
    Horiguchi, Jun
    Wake, Rei
    Hashioka, Sadayuki
    Thoyama, Masaya
    Murotani, Kenta
    Mori, Norio
    Minabe, Yoshio
    Iyo, Masaomi
    Ueno, Shuichi
    Ezoe, Sachiko
    Hoshino, Syuzo
    Seno, Haruo
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2015, 2015
  • [42] Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study
    Araujo-de-Freitas, Lucas
    Santos-Lima, Cassio
    Mendonca-Filho, Euclides
    Vieira, Flavia
    Franca, Ricardo J. A. F.
    Magnavita, Guilherme
    Cardoso, Tanise L.
    Correia-Melo, Fernanda S.
    Leal, Gustavo C.
    Jesus-Nunes, Ana Paula
    Souza-Marques, Breno
    Marback, Roberta
    Teles, Manuela
    Echegaray, Mariana V. F.
    Beanes, Graziele
    Guerreiro-Costa, Livia N. F.
    Mello, Rodrigo P.
    Rabanea, Thais
    Lucchese, Ana Cecilia
    Abreu, Neander
    Lacerda, Acioly L. T.
    Quarantini, Lucas C.
    PSYCHIATRY RESEARCH, 2021, 303
  • [43] Topiramate add-on in treatment-resistant schizophrenia:: A randomized, double-blind, placebo-controlled, crossover trial
    Tiihonen, J
    Halonen, P
    Wahlbeck, K
    Repo-Tiihonen, E
    Hyvärinen, S
    Eronen, M
    Putkonen, H
    Takala, P
    Mehtonen, IP
    Puck, M
    Oksanen, J
    Koskelainen, P
    Joffe, G
    Aer, J
    Hallikainen, T
    Ryynänen, IP
    Tupala, E
    JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (08) : 1012 - 1015
  • [44] A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder
    Cusin, Cristina
    Iovieno, Nadia
    Iosifescu, Dan V.
    Nierenberg, Andrew A.
    Fava, Maurizio
    Rush, A. John
    Perlis, Roy H.
    JOURNAL OF CLINICAL PSYCHIATRY, 2013, 74 (07) : E636 - E641
  • [45] Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial
    Mathew, Sanjay J.
    Murrough, James W.
    aan het Rot, Marije
    Collins, Katherine A.
    Reich, David L.
    Charney, Dennis S.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 (01): : 71 - 82
  • [46] A Randomized, Double-Blind, Placebo-Controlled Study of SEP-4199 for the Treatment of Patients With Bipolar Depression
    Loebel, Antony
    Koblan, Kenneth
    Kent, Justine
    Tsai, Joyce
    Ozol-Godfrey, Ayca
    Fava, Maurizio
    Hopkins, Seth
    NEUROPSYCHOPHARMACOLOGY, 2020, 45 (SUPPL 1) : 95 - 96
  • [47] A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder
    Gharabawi, G. M.
    Canuso, C. M.
    Pandina, G. J.
    Bossie, C. A.
    Kujawa, M.
    Kosik-Gonzalez, C.
    Turkoz, I.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S562 - S562
  • [48] A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder
    Gharabawi, G.
    Canuso, C.
    Pandina, G.
    Bossie, C.
    Kujawa, M.
    Kosik-Gonzalez, C.
    Turkoz, I.
    Papakostas, G. I.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S236 - S236
  • [49] Efficacy of pentoxifylline for the treatment of bipolar I/II patients with treatment-resistant depression: A proof-of-concept, randomized, double-blind, placebo-controlled trial
    Mohammad, Tavgah Ahmed Merza
    Mohammad, Talar Ahmed Merza
    Shawis, Teshk Nouri
    BRAIN RESEARCH BULLETIN, 2024, 216
  • [50] A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED CROSSOVER ADD-ON TRIAL OF LAMOTRIGINE IN PATIENTS WITH TREATMENT-RESISTANT PARTIAL SEIZURES
    LOISEAU, P
    YUEN, AWC
    DUCHE, B
    MENAGER, T
    ARNEBES, MC
    EPILEPSY RESEARCH, 1990, 7 (02) : 136 - 145
12345